Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: Pharmacokinetic consideration

Journal of Toxicological Sciences

Volumn 21, Issue 5, 1996, Pages 309-316

  Sugiyama, Yuichi ^a   Iwatsubo, Takafumi ^a   Ueda, Kaoru ^a   Ito, Kiyomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CIPROFLOXACIN; CYCLOSPORIN; DIAZEPAM; ERYTHROMYCIN; FLUOXETINE; IMIPRAMINE; KETOCONAZOLE; OMEPRAZOLE; QUINIDINE; SPARTEINE; SULFAPHENAZOLE; TERFENADINE; THEOPHYLLINE; TOLBUTAMIDE;

CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG INTOXICATION; DRUG MARKETING; DRUG METABOLISM; HUMAN; PREDICTION;

EID: 0030483051     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.21.5_309     Document Type: Conference Paper

References (12)

1. Back, D.J., Tjia, J.F., Karbwang, J. and Colbert, J. (1988): In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulfonamides and quinolines. Br. J. Clin. Pharmacol., 26, 23-29.
2. Christensen, L.K, Hansen, J.M. and Kristensen, M. (1963): Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet, 2, 1298-1301.
3. Fuse, E., Kobayashi, T., Inaba, M. and Sugiyama, Y. (1995): Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics. Cancer Treatment Reviews, 21, 133-157.
4. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H. and Sugiyama, Y. (1996): Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Disposit., 17, 273-310.
5. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C.E., Tyson, C.A. and Sugiyama, Y.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., in press.
6. Miners, J. O., Smith, K.J., Robson, R.A., McManus, M.E., Veronese, M.E. and Birkett, D.J. (1988): Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol., 37, 1137-1144.
7. Sugiyama, Y. and Iwatsubo, T. (1996): Alteration of pharmacokinetic features caused by drug interactions. Xenobio. Metabol. and Dispos., 11, 286-293.
8. Sugiyama, Y. and Ooie, T. (1993): Prediction of pharmacokinetics based on in vitro data. In: Methods and Techniques for Pharmacokinetic Studies (Sugiyama, Y., ed.), pp. 87-108, Japanese Society for the Study of Xenobiotics, Tokyo.
9. Thomas, R.C. and Ikeda, G.J. (1966): The metabolic fate of tolbutamide in man and in the rat. J. Med. Chem., 9, 507-510.
10. Veronese, M.E., Miners, J.O., Randles, D., Gregov, D. and Birkett, D.J. (1990): Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin. Pharmacol. Ther., 47, 403-411.
11. Wu, C.-Y., Benet, L.Z., Hebert, M.F., Gupta, S.K., Rowland, M., Gomez, D.Y. and Wacher, V.J. (1995): Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther., 58, 492-497.
12. Yamazaki, M., Nishigaki, R., Suzuki, H. and Sugiyama, Y. (1995): Kinetic analysis of hepatobiliary transport of drugs: Importance of carrier-mediated transport.